Cell No. : Cell Name
RCB0680 : HKBMM
update : 2024/11/14
|
| Comment | Human cell line derived from malignant meningioma. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Ishiwata, Isamu
|
| Originator |
Ishiwata, Isamu & Satou, Zenrou & Ishikawa, Hiroshi
|
| Year of deposit |
1991
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Gender |
Female
|
| Age at sampling |
48 years
|
| Tissue |
brain
|
| Disease name |
malignant meningioma
|
| Classification |
cancer
|
| Year of origin |
1991
|
| Memo_1 |
Mycoplasma was eliminated with MC-210 by the depositor.
|
|
Lifespan |
infinite
|
| Morphology |
other
|
| Cellosaurus(Expasy) |
CVCL_8162
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
HamF12 + 15% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : once/week, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Virus (HIV) |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
46-100(50) : 46(1),47(12),48(19),50(6),96(1),99(2)/
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
1
|
| User's Publication |
8
|
| User's Publication |
|
19756
Mitobe Y, Suzuki S, Nakagawa-Saito Y, Togashi K, Sugai A, Sonoda Y, Kitanaka C, Okada M.
The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo
Biomedicines
2023
11(7):1967
PubMed ID: 37509605
DOI: 10.3390/biomedicines11071967
|
|
18218
Nakano T, Fujimoto K, Tomiyama A, Takahashi M, Achiha T, Arita H, Kawauchi D, Yasukawa M, Masutomi K, Kondo A, Narita Y, Maehara T, Ichimura K.
Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma
Cancer Sci
2022
113(2):697-708
PubMed ID: 34839570
DOI: 10.1111/cas.15221
|
|
21145
Yamamoto M, Suzuki S, Togashi K, Sugai A, Okada M, Kitanaka C.
Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins.
Cancers (Basel)
2022
14(7)
PubMed ID: 35406478
DOI: 10.3390/cancers14071706
|
|
20220
Yamazaki S, Ohka F, Hirano M, Shiraki Y, Motomura K, Tanahashi K, Tsujiuchi T, Motomura A, Aoki K, Shinjo K, Murofushi Y, Kitano Y, Maeda S, Kato A, Shimizu H, Yamaguchi J, Adilijiang A, Wakabayashi T, Saito R, Enomoto A, Kondo Y, Natsume A.
Newly Established Patient-derived Organoid Model of Intracranial Meningioma.
Neuro Oncol
2021
PubMed ID: 34214169
DOI: 10.1093/neuonc/noab155
|
|
20472
Yamamoto M, Sanomachi T, Suzuki S, Togashi K, Sugai A, Seino S, Sato A, Okada M, Kitanaka C.
Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax.
Neurooncol Adv
2021
3(1):vdab148
PubMed ID: 34765973
DOI: 10.1093/noajnl/vdab148
|
|
16134
Yamamoto M, Sanomachi T, Suzuki S, Uchida H, Yonezawa H, Higa N, Takajo T, Yamada Y, Sugai A, Togashi K, Seino S, Okada M, Sonoda Y, Hirano H, Yoshimoto K, Kitanaka C.
Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
Neuro Oncol
2021
23(6):945-954
PubMed ID: 33556172
DOI: 10.1093/neuonc/noab015
|
|
11276
Ichikawa M, Akimoto J, Miki Y, Maeda J, Takahashi T, Fujiwara Y, Kohno M.
Photodynamic therapy with talaporfin sodium induces dose- and time-dependent apoptotic cell death in malignant meningioma HKBMM cells.
Photodiagnosis Photodyn Ther
2019
PubMed ID: 30389626
DOI: 10.1016/j.pdpdt.2018.10.022
|
|
14614
Takeda H, Okada M, Kuramoto K, Suzuki S, Sakaki H, Sanomachi T, Seino S, Yoshioka T, Hirano H, Arita K, Kitanaka C.
Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo
Oncotarget
2017
8(53):90996-91008
PubMed ID: 29207619
DOI: 10.18632/oncotarget.18827
|
Back
Top
CELL BANK Website